SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) – SVB Leerink reduced their Q3 2022 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on Monday, August 8th. SVB Leerink analyst A. Berens now anticipates that the company will earn ($2.19) per share for the quarter, down from their previous estimate of ($1.78). SVB Leerink has a "Market Perform" rating and a $76.00 price objective on the stock. The consensus estimate for Turning Point Therapeutics' current full-year earnings is ($6.85) per share. SVB Leerink also issued estimates for Turning Point Therapeutics' Q4 2022 earnings at ($2.24) EPS, FY2022 earnings at ($8.42) EPS, FY2023 earnings at ($9.38) EPS, FY2024 earnings at ($5.84) EPS, FY2025 earnings at $1.56 EPS and FY2026 earnings at $12.31 EPS.
Turning Point治疗公司(纳斯达克代码：TPTX-GET评级)-SVB Leerink在8月8日星期一发布给客户和投资者的一份研究报告中下调了他们对Turning Point治疗公司2022年第三季度每股收益的估计。SVB Leerink分析师A.Berens现在预计，该公司本季度每股收益为2.19美元，低于此前预测的1.78美元。SVB Leerink给予该股“市场表现”的评级和76.00美元的目标价。对Turning Point Treateutics目前全年收益的普遍估计为每股6.85美元。SVB Leerink还发布了对Turning Point Treeutics 2022财年第四季度每股收益(2.24美元)、2022财年每股收益(8.42美元)、2023财年每股收益(9.38美元)、2024财年每股收益(5.84美元)、2025财年每股收益1.56美元和2026财年每股收益12.31美元的预期。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.78). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $2.27 million. During the same quarter in the prior year, the firm earned ($1.14) EPS. The company's revenue for the quarter was down 97.7% compared to the same quarter last year.
Turning Point Treateutics(纳斯达克：多伦多证券交易所股票代码：GET)最近一次发布收益报告是在8月8日星期一。该公司公布本季度每股收益(2.48美元)，低于(1.70美元)和(0.78美元)的普遍预期。该业务本季度的收入为12万美元，而普遍预期为227万美元。去年同一季度，该公司每股收益为1.14美元。与去年同期相比，该公司本季度的收入下降了97.7%。
Turning Point Therapeutics Price Performance
转折点治疗性价比
Shares of NASDAQ TPTX opened at $75.00 on Thursday. Turning Point Therapeutics has a 12-month low of $23.77 and a 12-month high of $82.20. The company has a market capitalization of $3.72 billion, a PE ratio of -10.87 and a beta of -0.18. The firm's 50-day moving average is $74.94 and its two-hundred day moving average is $46.41.
周四，纳斯达克TPTX的股价开盘报75.00美元。Turning Point Treeutics的12个月低点为23.77美元，12个月高位为82.20美元。该公司市值为37.2亿美元，市盈率为-10.87，贝塔系数为-0.18。该公司50日移动均线切入位在74.94美元，200日移动均线切入位在46.41美元。
Insider Activity at Turning Point Therapeutics
转折点治疗公司的内部活动
In related news, CFO Paolo Tombesi sold 1,183 shares of the company's stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the transaction, the chief financial officer now owns 28,700 shares of the company's stock, valued at $2,150,778. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.60% of the company's stock.
在相关新闻中，首席财务官保罗·汤贝西在7月27日星期三的一笔交易中出售了1,183股该公司股票。这些股票的平均价格为74.94美元，总成交金额为88,654.02美元。交易完成后，这位首席财务官现在持有该公司28,700股股票，价值2,150,778美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份法律文件中披露的，可以通过这个链接访问。内部人士持有该公司8.60%的股份。
Hedge Funds Weigh In On Turning Point Therapeutics
对冲基金参与转折点治疗
A number of large investors have recently bought and sold shares of TPTX. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Turning Point Therapeutics by 35.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,692 shares of the company's stock worth $319,000 after purchasing an additional 1,744 shares during the period. DekaBank Deutsche Girozentrale raised its stake in Turning Point Therapeutics by 2.4% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 16,870 shares of the company's stock worth $789,000 after purchasing an additional 400 shares during the period. Duality Advisers LP purchased a new position in Turning Point Therapeutics during the fourth quarter worth approximately $1,451,000. Nisa Investment Advisors LLC raised its stake in Turning Point Therapeutics by 489.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,850 shares of the company's stock worth $516,000 after purchasing an additional 11,500 shares during the period. Finally, Virginia Retirement Systems ET AL raised its stake in Turning Point Therapeutics by 5.4% during the fourth quarter. Virginia Retirement Systems ET AL now owns 11,700 shares of the company's stock worth $558,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 90.33% of the company's stock.
一些大型投资者最近买卖了TPTX的股票。苏黎世广东银行在第四季度将其在Turning Point Treeutics的持股增加了35.2%。Zurcher Kantonalbank苏黎世广东银行在此期间又购买了1,744股，现在持有该公司6,692股股票，价值319,000美元。DekaBank Deutsche Girozentale在第四季度将其在Turning Point Treeutics的股份增加了2.4%。在此期间，德意志银行又购买了400股，现在持有16,870股该公司股票，价值78.9万美元。Duality Advisers LP在第四季度购买了Turning Point Treeutics的一个新头寸，价值约1,451,000美元。NISA Investment Advisors LLC在第四季度将其在Turning Point Treateutics的持股增加了489.4%。NISA Investment Advisors LLC现在拥有13,850股该公司股票，价值516,000美元，在此期间又购买了11,500股。最后，弗吉尼亚退休系统等公司在第四季度将其在Turning Point Treateutics的股份增加了5.4%。弗吉尼亚退休系统等公司现在拥有11,700股该公司的股票，价值55.8万美元，在此期间又购买了600股。对冲基金和其他机构投资者持有该公司90.33%的股票。
About Turning Point Therapeutics
关于转折点疗法
(Get Rating)
(获取评级)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治疗公司是一家临床阶段的精确肿瘤学生物制药公司，致力于设计和开发针对癌症遗传驱动因素的治疗方法。它开发了一系列酪氨酸激酶抑制剂(TKI)，针对TKI-NAI、̈Ve和TKI预治疗患者的癌症基因驱动因素。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免费获取StockNews.com关于转折点治疗(TPTX)的研究报告
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票？
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
- 清洁能源法案通过后，太阳能股大放异彩
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《转折点治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Turning Point Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。